ABL Bio, First Disclosure of Preclinical Data for Dual Antibody 'ABL603' Targeting Stomach and Pancreatic Cancer

[Asia Economy Reporter Chunhee Lee] ABL Bio, a bispecific antibody specialist company ABL Bio, announced on the 10th that it will unveil the preclinical data of 'ABL603' for the first time at the '14th European Protein & Antibody Engineering Summit (PEGS Europe Protein & Antibody Engineering Summit)'.

PEGS Europe is the largest event in Europe for sharing expertise and the latest information on protein and antibody engineering. It will be held for three days from the 14th to the 16th (local time) in Barcelona, Spain. ABL Bio will present the in vivo and in vitro experimental results of ABL603 in a poster session at this event.

ABL603 is a bispecific antibody pipeline that simultaneously targets 'Claudin18.2', which is overexpressed in gastric and pancreatic cancers, and 'CD3', which is involved in T cell activation. It is designed with a 2+1 asymmetrical structure using a CD3-based bispecific antibody platform. It has a mechanism that activates T cells only in the tumor microenvironment where Claudin18.2 is expressed.

Claudin18.2 is limitedly expressed in normal tissues but tends to be highly expressed in gastric and pancreatic cancers, making it an ideal anticancer target for T cell engager development. It is being developed in various forms such as bispecific antibodies, antibody-drug conjugates (ADC), and chimeric antigen receptor (CAR)-T cells.

Lee Sang-hoon, CEO of ABL Bio, said, “We are pleased to introduce ABL603, which applies our CD3 bispecific antibody platform following ABL602, for the first time on a global stage such as PEGS Europe,” adding, “Claudin18.2 is emerging as a major anticancer target for gastric and pancreatic cancer treatment, and interest in T cell engagers such as CD3 is also increasing, which highly values the development potential of ABL603.”

This content was produced with the assistance of AI translation services.